Stockscreener 앱 받기
6.10
1.16%
0.07
시간 외 거래:
6.12
0.02
+0.33%
전일 마감가:
$6.03
열려 있는:
$6
하루 거래량:
2.12M
Relative Volume:
1.33
시가총액:
$618.31M
수익:
-
순이익/손실:
$-167.48M
주가수익비율:
-3.1282
EPS:
-1.95
순현금흐름:
$-197.47M
1주 성능:
-8.27%
1개월 성능:
-7.72%
6개월 성능:
-49.38%
1년 성능:
-53.54%
1일 변동 폭
$5.8503
$6.12
1주일 범위
$5.635
$7.0399
52주 변동 폭
$5.635
$16.76
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
명칭
Day One Biopharmaceuticals Inc
전화
650 484-0899
주소
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
6.10 | 594.11M | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-09 | 재확인 | Needham | Buy |
| 2024-08-01 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2024-04-24 | 재확인 | Needham | Buy |
| 2023-04-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-02-08 | 개시 | CapitalOne | Overweight |
| 2023-02-03 | 개시 | Oppenheimer | Perform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-12-05 | 개시 | Goldman | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
모두보기
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
Day One Biopharmaceutical Stock Price, Quotes and Forecasts | NASDAQ:DAWN - Benzinga
Day One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade) - Seeking Alpha
Day One Biopharmaceuticals Maintains Buy Rating on Promising Growth and Strategic Innovation - AInvest
A Quick Look at Today's Ratings for Day One Biopharmaceuticals(DAWN.US), With a Forecast Between $16 to $26 - 富途牛牛
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q2 2025 Earnings Call Transcript - Insider Monkey
Day One Biopharma’s Earnings Call Highlights Growth and Strategy - TipRanks
Promising Growth and Strategic Innovation Drive Buy Rating for Day One Biopharmaceuticals - TipRanks
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Day One Biopharmaceuticals Plunges 13.95% Despite Revenue Surge - AInvest
Day One Biopharmaceuticals shares fall 14.24% premarket after Q2 2025 earnings call. - AInvest
Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate - MSN
Day One Biopharmaceuticals (DAWN): A High-Growth Biotech Play in Pediatric Oncology with a Clear Path to Value Creation - AInvest
Day One Biopharmaceuticals Inc (DAWN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Day One Biopharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Day One Biopharma Reports Strong Q2 2025 Growth - TipRanks
Day One Biopharmaceuticals Reports Q2 2025 Financial Results and Strategic Appointments. - AInvest
Day One Biopharmaceuticals' Q2 2025: Unpacking Contradictions in Treatment Durability, Financial Projections, and Growth Trajectory - AInvest
Day One Biopharmaceuticals: Scaling OJEMDA Revenue While Strengthening R&D and Financial Discipline - AInvest
Transcript : Day One Biopharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Day One Biopharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:DAWN) - Seeking Alpha
Day One Biopharmaceuticals earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Day One Biopharma Q2 2025 revenue growth impresses - Investing.com Canada
Day One Biopharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Day One Biopharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Day One Biopharmaceuticals reports Q2 EPS (29c), consensus (34c) - TipRanks
Day One Biopharmaceuticals Q2 Revenue Rises Amid Leadership Changes and Earnings Calls - AInvest
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress - The Manila Times
Day One Biopharmaceuticals Reports Q2 2025 Financial Results, Expects $140-150M in OJEMDA Net Product Revenue for FY25 - AInvest
What are analysts’ price targets for Day One Biopharmaceuticals Inc. in the next 12 monthsFree Stock Selection - Jammu Links News
How volatile is Day One Biopharmaceuticals Inc. stock compared to the marketDiscover hidden gems in the stock market - Jammu Links News
What is the risk reward ratio of investing in Day One Biopharmaceuticals Inc. stock - Jammu Links News
Is it the right time to buy Day One Biopharmaceuticals Inc. stockCapitalize on high-yield stock opportunities - Jammu Links News
Day One Biopharmaceuticals Inc. Stock Analysis and ForecastCapitalize on emerging trends for profits - Jammu Links News
Why is Day One Biopharmaceuticals Inc. stock attracting strong analyst attentionFree Investment Community - Jammu Links News
How does Day One Biopharmaceuticals Inc. generate profit in a changing economyTremendous growth opportunities - Jammu Links News
Is Day One Biopharmaceuticals Inc. a growth stock or a value stockBuild a portfolio that withstands market volatility - Jammu Links News
How many analysts rate Day One Biopharmaceuticals Inc. as a “Buy”Unbelievable profit margins - Jammu Links News
What are the technical indicators suggesting about Day One Biopharmaceuticals Inc.Build a portfolio that outperforms consistently - Jammu Links News
Does Day One Biopharmaceuticals Inc. stock perform well during market downturnsPhenomenal trading returns - Jammu Links News
How strong is Day One Biopharmaceuticals Inc. company’s balance sheetInvest smarter with cutting-edge analytics - Jammu Links News
What makes Day One Biopharmaceuticals Inc. stock price move sharplyInvest smarter with daily market updates - Jammu Links News
Can a trend reversal in Day One Biopharmaceuticals Inc. lead to recoveryYield Curve Outlook and Long-Term Implication Summary - Newser
Day One Biopharmaceuticals Inc. stock chart pattern explainedRisk/Reward Optimization Entry Point Analysis - Newser
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025 - 富途牛牛
Published on: 2025-07-30 22:40:17 - Newser
Can Day One Biopharmaceuticals Inc. recover in the next quarterWeekly Stock Opportunity Radar Scanner Activated - metal.it
How Day One Biopharmaceuticals Inc. stock performs during market volatilityNeural Model for Stock Price Movement - Newser
Published on: 2025-07-30 04:25:27 - Newser
Trapped Investors in Day One Biopharmaceuticals Inc. Await Breakout SignalMulti-Bagger Potential Stock Forecast Tools Released - beatles.ru
How institutional ownership impacts Day One Biopharmaceuticals Inc. stockFree Short Term Buy Zone Stock Alerts - Newser
Comparing Day One Biopharmaceuticals Inc. in custom built stock radarsAsset Growth Pattern and Return Summary - Newser
Day One Biopharmaceuticals Inc (DAWN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):